Literature DB >> 21976658

Infection with seasonal influenza virus elicits CD4 T cells specific for genetically conserved epitopes that can be rapidly mobilized for protective immunity to pandemic H1N1 influenza virus.

Shabnam Alam1, Andrea J Sant.   

Abstract

In recent years, influenza viruses with pandemic potential have been a major concern worldwide. One unresolved issue is how infection or vaccination with seasonal influenza virus strains influences the ability to mount a protective immune response to novel pandemic strains. In this study, we developed a mouse model of primary and secondary influenza infection by using a widely circulating seasonal H1N1 virus and the pandemic strain of H1N1 that emerged in Mexico in 2009, and we evaluated several key issues. First, using overlapping peptide libraries encompassing the entire translated sequences of 5 major influenza virus proteins, we assessed the specificity of CD4 T cell reactivity toward epitopes conserved among H1N1 viruses or unique to the seasonal or pandemic strain by enzyme-linked immunospot (ELISpot) assays. Our data show that CD4 T cells reactive to both virus-specific and genetically conserved epitopes are elicited, allowing separate tracking of these responses. Populations of cross-reactive CD4 T cells generated from seasonal influenza infection were found to expand earlier after secondary infection with the pandemic H1N1 virus than CD4 T cell populations specific for new epitopes. Coincident with this rapid CD4 T cell response was a potentiated neutralizing-antibody response to the pandemic strain and protection from the pathological effects of infection with the pandemic virus. This protection was not dependent on CD8 T cells. Together, our results indicate that exposure to seasonal vaccines and infection elicits CD4 T cells that promote the ability of the mammalian host to mount a protective immune response to pandemic strains of influenza virus.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21976658      PMCID: PMC3233140          DOI: 10.1128/JVI.05728-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  69 in total

Review 1.  Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target.

Authors:  Neetu Singh; Aseem Pandey; Suresh K Mittal
Journal:  Expert Rev Mol Med       Date:  2010-04-29       Impact factor: 5.600

Review 2.  Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection.

Authors:  Edgar Bautista; Tawee Chotpitayasunondh; Zhancheng Gao; Scott A Harper; Michael Shaw; Timothy M Uyeki; Sherif R Zaki; Frederick G Hayden; David S Hui; Joel D Kettner; Anand Kumar; Matthew Lim; Nahoko Shindo; Charles Penn; Karl G Nicholson
Journal:  N Engl J Med       Date:  2010-05-06       Impact factor: 91.245

Review 3.  The potential of CD4 T-cell memory.

Authors:  K Kai McKinstry; Tara M Strutt; Susan L Swain
Journal:  Immunology       Date:  2010-03-16       Impact factor: 7.397

Review 4.  Prospects for an influenza vaccine that induces cross-protective cytotoxic T lymphocytes.

Authors:  Lorena E Brown; Anne Kelso
Journal:  Immunol Cell Biol       Date:  2009-03-24       Impact factor: 5.126

5.  Analyses of the specificity of CD4 T cells during the primary immune response to influenza virus reveals dramatic MHC-linked asymmetries in reactivity to individual viral proteins.

Authors:  Jennifer L Nayak; Katherine A Richards; Francisco A Chaves; Andrea J Sant
Journal:  Viral Immunol       Date:  2010-04       Impact factor: 2.257

Review 6.  Keeping the memory of influenza viruses.

Authors:  B Combadière; S Sibéril; D Duffy
Journal:  Pathol Biol (Paris)       Date:  2010-03-19

Review 7.  Biochemical signaling pathways for memory T cell recall.

Authors:  Donna L Farber
Journal:  Semin Immunol       Date:  2009-04       Impact factor: 11.130

8.  Functionally diverse subsets in CD4 T cell responses against influenza.

Authors:  Tara M Strutt; K Kai McKinstry; Susan L Swain
Journal:  J Clin Immunol       Date:  2008-12-03       Impact factor: 8.317

9.  Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities.

Authors:  Alessandro Sette; Magdalini Moutaftsi; Juan Moyron-Quiroz; Megan M McCausland; D Huw Davies; Robert J Johnston; Bjoern Peters; Mohammed Rafii-El-Idrissi Benhnia; Julia Hoffmann; Hua-Poo Su; Kavita Singh; David N Garboczi; Steven Head; Howard Grey; Philip L Felgner; Shane Crotty
Journal:  Immunity       Date:  2008-06       Impact factor: 31.745

10.  Host genetic background strongly influences the response to influenza a virus infections.

Authors:  Barkha Srivastava; Paulina Błazejewska; Manuela Hessmann; Dunja Bruder; Robert Geffers; Susanne Mauel; Achim D Gruber; Klaus Schughart
Journal:  PLoS One       Date:  2009-03-18       Impact factor: 3.240

View more
  36 in total

1.  Competition within the virus-specific CD4 T-cell pool limits the T follicular helper response after influenza infection.

Authors:  Matthew R Olson; Brendon Y Chua; Kim L Good-Jacobson; Peter C Doherty; David C Jackson; Stephen J Turner
Journal:  Immunol Cell Biol       Date:  2016-04-22       Impact factor: 5.126

2.  Cold-adapted pandemic 2009 H1N1 influenza virus live vaccine elicits cross-reactive immune responses against seasonal and H5 influenza A viruses.

Authors:  Yo Han Jang; Young Ho Byun; Yoon Jae Lee; Yun Ha Lee; Kwang-Hee Lee; Baik Lin Seong
Journal:  J Virol       Date:  2012-03-21       Impact factor: 5.103

3.  Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin.

Authors:  Michela Brazzoli; Diletta Magini; Alessandra Bonci; Scilla Buccato; Cinzia Giovani; Roland Kratzer; Vanessa Zurli; Simona Mangiavacchi; Daniele Casini; Luis M Brito; Ennio De Gregorio; Peter W Mason; Jeffrey B Ulmer; Andrew J Geall; Sylvie Bertholet
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

Review 4.  Distinct and complementary roles of CD4 T cells in protective immunity to influenza virus.

Authors:  Andrea J Sant; Katherine A Richards; Jennifer Nayak
Journal:  Curr Opin Immunol       Date:  2018-04-02       Impact factor: 7.486

Review 5.  Early programming and late-acting checkpoints governing the development of CD4 T-cell memory.

Authors:  Kunal Dhume; Karl Kai McKinstry
Journal:  Immunology       Date:  2018-05-21       Impact factor: 7.397

6.  Protein Vaccination Directs the CD4+ T Cell Response toward Shared Protective Epitopes That Can Be Recalled after Influenza Virus Infection.

Authors:  Ajitanuj Rattan; Katherine A Richards; Zackery A G Knowlden; Andrea J Sant
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

7.  CD4 T cell help is limiting and selective during the primary B cell response to influenza virus infection.

Authors:  Shabnam Alam; Zackery A G Knowlden; Mark Y Sangster; Andrea J Sant
Journal:  J Virol       Date:  2013-10-23       Impact factor: 5.103

8.  Trivalent inactivated influenza vaccines induce broad immunological reactivity to both internal virion components and influenza surface proteins.

Authors:  Katherine A Richards; Francisco A Chaves; Shabnam Alam; Andrea J Sant
Journal:  Vaccine       Date:  2012-10-22       Impact factor: 3.641

9.  Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice.

Authors:  Joseph N Brewoo; Tim D Powell; Jeremy C Jones; Nancy A Gundlach; Ginger R Young; Haiyan Chu; Subash C Das; Charalambos D Partidos; Dan T Stinchcomb; Jorge E Osorio
Journal:  Vaccine       Date:  2013-02-01       Impact factor: 3.641

10.  The parasite-derived rOv-ASP-1 is an effective antigen-sparing CD4+ T cell-dependent adjuvant for the trivalent inactivated influenza vaccine, and functions in the absence of MyD88 pathway.

Authors:  Sonia Jain; Parakkal Jovvian George; Wanyan Deng; Joseph Koussa; Kaela Parkhouse; Scott E Hensley; Jiu Jiang; Jie Lu; Zhuyun Liu; Junfei Wei; Bin Zhan; Maria Elena Bottazzi; Hao Shen; Sara Lustigman
Journal:  Vaccine       Date:  2018-06-14       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.